Omnitrope (somatropin) is a brand-name drug that’s prescribed for growth hormone deficiency and other conditions. It comes as a subcutaneous injection that’s typically given once daily. The dosage can ...

Omnitrope is a brand-name injectable solution prescribed for growth hormone deficiency in adults and children. It contains the active ingredient somatropin. Omnitrope may not be safe to receive during ...

• Now approved in US for full range of reference product indications Princeton, New Jersey, August 31, 2011 - Sandoz announced today that the US Food and Drug Administration (FDA) has approved its ...

The prescribed dosage for Omnitrope (somatropin) may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage of Omnitrope. Omnitrope ...

Omnitrope (somatropin) has potential interactions with other medications. For example, Omnitrope can interact with corticosteroids and certain diabetes medications. Doctors prescribe Omnitrope for ...

When Sarah Sellers heard on May 31 that the U.S. Food & Drug Administration had approved a generic-like version of human growth hormone (HGH), she was less than thrilled. The product, called Omnitrope ...

Novartis' generic drug unit Sandoz has won European Commission approval to market Omnitrope, a human growth hormone that will become the first new biosimilar to hit the market. Sandoz expects to waste ...

The National Institute for Health and Clinical Excellence has approved the use of Sandoz’ Omnitrope on the National Health Service, marking the first time it has recommended a biosimilar medicine. The ...

Sandoz (Holzkirchen, Germany), the generics arm of Novartis (Basel, Switzerland), received approval from the US Food and Drug Administration (Rockville, MD) for "Omnitrope" (somatropin [rDNA origin]), ...

PRINCETON, N.J. The Food and Drug Administrations has approved two new uses for what remains, thus far, the only biosimilar on the U.S. market. Sandoz, the generics arm of Swiss drug maker Novartis, ...